A clinical trial update for tirzepatide was recorded on August 7, 2026. The study, titled "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)," is registered under identifier NCT06439277.
The trial is listed as Phase 3 and is currently in RECRUITING status. It is designed to study tirzepatide in adolescents with obesity and weight-related comorbidities.
No results have been posted for this trial at this time. The status reflects only that participant recruitment is ongoing, not any findings, benefits, or risks associated with tirzepatide.
Tirzepatide is currently an approved compound. This trial update does not change its approved regulatory status.
Readers seeking additional detail on this study can consult the official listing at ClinicalTrials.gov under the identifier NCT06439277. For general background on tirzepatide, see the compound overview.